Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 18.57% is 38% above its 5-year average of 13.48%, near the high end of its 5-year range (-11.16%–30.29%).
0.17% above its 12-month average of 18.54%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 20.59%.
GROSS MARGIN
18.57%
GROSS MARGIN AVG TTM
18.54%
GROSS MARGIN AVG 3Y
23.21%
GROSS MARGIN AVG 5Y
13.48%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+0.17%
CURRENT VS 3Y AVG
-20.00%
CURRENT VS 5Y AVG
+37.78%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
42.91%
median of 560 covered companies
CURRENT VS SECTOR MEDIAN
-56.72%
vs the sector median at left
Clover Health Investments, Corp.
Market Cap
$2.40B
Gross Margin
18.57%
TTM Avg
18.54%
3Y Avg
23.21%
5Y Avg
13.48%
Market Cap
$2.43B
Gross Margin
-61.96%
TTM Avg
-19.42%
3Y Avg
-14.39%
5Y Avg
23.74%
Market Cap
$2.33B
Gross Margin
64.71%
TTM Avg
54.44%
3Y Avg
41.55%
5Y Avg
20.41%
Market Cap
$2.45B
Gross Margin
92.48%
TTM Avg
74.82%
3Y Avg
78.80%
5Y Avg
76.59%
Market Cap
$2.30B
Gross Margin
17.98%
TTM Avg
29.88%
3Y Avg
47.29%
5Y Avg
57.26%
Market Cap
$2.29B
Gross Margin
75.42%
TTM Avg
77.61%
3Y Avg
78.83%
5Y Avg
79.96%
Market Cap
$2.52B
Gross Margin
56.20%
TTM Avg
28.10%
3Y Avg
28.10%
5Y Avg
28.10%
Market Cap
$2.15B
Gross Margin
17.11%
TTM Avg
17.72%
3Y Avg
20.44%
5Y Avg
20.08%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Clover Health Investments, Corp. (CLOV) | $2.40B | 18.57% | 18.54% | 23.21% | 13.48% |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.43B | -61.96% | -19.42% | -14.39% | 23.74% |
| Disc Medicine, Inc. (IRON)vs › | $2.44B | 0.00% | 0.00% | 0.00% | 0.00% |
| ADMA Biologics, Inc. (ADMA)vs › | $2.33B | 64.71% | 54.44% | 41.55% | 20.41% |
| Liquidia Corporation (LQDA)vs › | $2.45B | 92.48% | 74.82% | 78.80% | 76.59% |
| Maravai LifeSciences Holdings, Inc. (MRVI)vs › | $2.30B | 17.98% | 29.88% | 47.29% | 57.26% |
| Harmony Biosciences Holdings, Inc. (HRMY)vs › | $2.29B | 75.42% | 77.61% | 78.83% | 79.96% |
| Alamar Biosciences, Inc. (ALMR)vs › | $2.52B | 56.20% | 28.10% | 28.10% | 28.10% |
| Fortrea Holdings Inc. (FTRE)vs › | $2.15B | 17.11% | 17.72% | 20.44% | 20.08% |
| Beam Therapeutics Inc. (BEAM)vs › | $2.60B | 84.05% | -197.31% | -176.53% | -71811.06% |
Gross Margin
18.6%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 20.59% |
| 2026-03-31 | 21.30% |
| 2025-12-31 | 15.22% |
| 2025-09-30 | 14.73% |
| 2025-06-30 | 20.86% |
| 2025-03-31 | 23.55% |
| 2024-12-31 | 27.87% |
| 2024-09-30 | 24.54% |
| 2024-06-30 | 30.29% |
| 2024-03-31 | 23.57% |
| 2023-12-31 | 12.20% |
| 2023-09-30 | 22.95% |
| 2023-06-30 | 23.70% |
| 2023-03-31 | 14.66% |
| 2022-12-31 | 0.57% |
| 2022-09-30 | 1.99% |
| 2022-06-30 | -1.43% |
| 2022-03-31 | 1.45% |
| 2021-12-31 | -2.26% |
| 2021-09-30 | -2.14% |
| 2021-06-30 | -11.16% |
| 2021-03-31 | -7.04% |
| 2020-12-31 | -8.01% |
| 2020-09-30 | 14.33% |
| 2020-06-30 | 30.63% |
| 2020-03-31 | 11.59% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 100.00% |
| 2019-06-30 | 100.00% |
| 2019-03-31 | 100.00% |
